RHBDD3

Across TCGA pan-cancer cohorts, RHBDD3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RHBDD3 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RHBDD3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RHBDD3 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

CCRCC, LUAD, and HNSC are the cancer types where RHBDD3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.702	1.000	.005	29	view →
LUAD	OS	Tertile	II,III,IV	0.449	0.846	.005	28	view →
HNSC	OS	Tertile	II,III,IV	1.000	0.941	.030	4	view →
LSCC	DFS	Quartile	II,III,IV	0.284	0.921	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RHBDD3–CCRCC (DFS)

Open the CCRCC breakdown →